Herantis Pharma Oyj (HEL:HRTIS)
Finland
· Delayed Price · Currency is EUR 1.890
-0.100 (-5.03%)
At close: Mar 9, 2026
Herantis Pharma Oyj Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 0.75 | 0.63 | 5.5 | 5.04 | 6.44 | Upgrade
|
| Short-Term Investments | 1.85 | 1.5 | 0.99 | 0.96 | 0.99 | Upgrade
|
| Cash & Short-Term Investments | 2.6 | 2.13 | 6.49 | 5.99 | 7.42 | Upgrade
|
| Cash Growth | 21.67% | -67.10% | 8.30% | -19.31% | -44.28% | Upgrade
|
| Other Receivables | 0.04 | 0.41 | 0.24 | 0.2 | 0.12 | Upgrade
|
| Receivables | 0.04 | 0.41 | 0.24 | 0.2 | 0.12 | Upgrade
|
| Prepaid Expenses | 0.04 | 0.03 | 0.02 | 0.04 | 0.06 | Upgrade
|
| Other Current Assets | -0 | - | - | - | - | Upgrade
|
| Total Current Assets | 2.67 | 2.57 | 6.75 | 6.23 | 7.6 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.16 | Upgrade
|
| Total Assets | 2.67 | 2.57 | 6.75 | 6.23 | 7.76 | Upgrade
|
| Accounts Payable | 0.39 | 0.28 | 0.75 | 0.66 | 0.79 | Upgrade
|
| Accrued Expenses | 0.49 | 0.28 | 1.17 | 1.06 | 0.73 | Upgrade
|
| Current Portion of Long-Term Debt | 0.01 | 0 | 0 | 0.15 | 0.91 | Upgrade
|
| Current Portion of Leases | - | 0.04 | - | - | 0.13 | Upgrade
|
| Other Current Liabilities | 0.03 | 0.03 | 0.06 | 0.03 | 0.05 | Upgrade
|
| Total Current Liabilities | 0.91 | 0.63 | 1.99 | 1.9 | 2.61 | Upgrade
|
| Long-Term Debt | 0.02 | 0.02 | 0.03 | 4.39 | 6.29 | Upgrade
|
| Other Long-Term Liabilities | 3.42 | 2.16 | - | - | 0 | Upgrade
|
| Total Liabilities | 4.36 | 2.81 | 2.02 | 6.29 | 8.9 | Upgrade
|
| Common Stock | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | Upgrade
|
| Retained Earnings | -86.71 | -80.07 | -75.1 | -75.38 | -67.75 | Upgrade
|
| Comprehensive Income & Other | 84.94 | 79.75 | 79.75 | 75.24 | 66.53 | Upgrade
|
| Shareholders' Equity | -1.69 | -0.24 | 4.73 | -0.06 | -1.14 | Upgrade
|
| Total Liabilities & Equity | 2.67 | 2.57 | 6.75 | 6.23 | 7.76 | Upgrade
|
| Total Debt | 0.03 | 0.07 | 0.03 | 4.54 | 7.33 | Upgrade
|
| Net Cash (Debt) | 2.57 | 2.06 | 6.45 | 1.45 | 0.09 | Upgrade
|
| Net Cash Growth | 24.82% | -68.07% | 345.14% | 1482.98% | -98.50% | Upgrade
|
| Net Cash Per Share | 0.11 | 0.10 | 0.38 | 0.10 | 0.01 | Upgrade
|
| Filing Date Shares Outstanding | 23.19 | 20.16 | 20.16 | 16.91 | 11.1 | Upgrade
|
| Total Common Shares Outstanding | 23.19 | 20.16 | 20.16 | 16.91 | 11.1 | Upgrade
|
| Working Capital | 1.76 | 1.94 | 4.76 | 4.33 | 4.99 | Upgrade
|
| Book Value Per Share | -0.07 | -0.01 | 0.23 | -0.00 | -0.10 | Upgrade
|
| Tangible Book Value | -1.69 | -0.24 | 4.73 | -0.06 | -1.14 | Upgrade
|
| Tangible Book Value Per Share | -0.07 | -0.01 | 0.23 | -0.00 | -0.10 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.